Jade Biosciences (JBIO) Corporate presentation summary

Strategic focus and financial position

• Advancing best-in-class therapies for autoimmune diseases, with a focus on IgA nephropathy (IgAN) and other systemic autoimmune indications.

• $336 million in cash as of December 31, 2025, providing runway into the first half of 2028.

• Pipeline includes JADE101 (anti-APRIL), JADE201 (anti-BAFF-R), and JADE301 (undisclosed), with exclusive licenses from Paragon Therapeutics for the first two programs.

• Programs are designed for infrequent, patient-friendly dosing and to maximize clinical responses.

• 70.7 million shares outstanding as of December 12, 2025.

JADE101: Anti-APRIL mAb for IgAN

• Targets a $10B+ U.S. branded market with significant unmet need for long-term, disease-modifying therapies in young adults.

• Designed for ultra-high affinity, extended half-life, and potentially best-in-class efficacy with ≤6 injections per year.

• Avoids broad B-cell depletion, selectively targeting APRIL to reduce pathogenic IgA and proteinuria while stabilizing kidney function.

• Demonstrates superior APRIL binding affinity and slow off-rate compared to other anti-APRILs in development.

• Phase 1 healthy volunteer trial ongoing, with interim biomarker-rich data expected in 1H 2026 to inform dose selection for IgAN patients.

Market and clinical landscape for IgAN

• IgAN affects over 1 million patients globally, with 169,000+ in the U.S.; 60-75% require treatment per guidelines.

• Updated KDIGO guidelines position anti-APRIL as foundational therapy, expanding the treatable patient population and lowering proteinuria targets.

• Clinical data show selective APRIL inhibition yields greater proteinuria reduction and remission rates than dual APRIL/BAFF or BAFF-only approaches.

• Minimizing injection burden is a key advantage for lifelong therapy in young adults.